title: BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.
abstract: BRAF inhibitors vemurafenib and dabrafenib achieved improved overall survival over chemotherapy and have been approved for the treatment of BRAF-mutated metastatic melanoma. More recently, the combination of BRAF inhibitor dabrafenib with MEK inhibitor trametinib has shown improved progression-free survival, compared to dabrafenib monotherapy, in a Phase II study and has received approval by the US Food and Drug Administration. However, even when treated with the combination, most patients develop mechanisms of acquired resistance, and some of them do not achieve tumor regression at all, because of intrinsic resistance to therapy. Along with the development of BRAF inhibitors, immunotherapy made an important step forward: ipilimumab, an anti-CTLA-4 monoclonal antibody, was approved for the treatment of metastatic melanoma; anti-PD-1 agents achieved promising results in Phase I/II trials, and data from Phase III studies will be ready soon. The availability of such drugs, which are effective regardless of BRAF status, has made the therapeutic approach more complex, as first-line treatment with BRAF inhibitors may not be the best choice for all BRAF-mutated patients. The aim of this paper is to review the systemic therapeutic options available today for patients affected by BRAF V600-mutated metastatic melanoma, as well as to summarize the mechanisms of resistance to BRAF inhibitors and discuss the possible strategies to overcome them. Moreover, since the molecular analysis of tumor specimens is now a pivotal and decisional factor in the treatment strategy of metastatic melanoma patients, the advances in the molecular detection techniques for the BRAF V600 mutation will be reported.
authors: Department of Plastic and Reconstructive Surgery, IRCCS Azienda Ospedaliera Universitaria San Martino, IST Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy.
authors: Francesco
authors: F
authors: Spagnolo
authors: Department of Internal Medicine and Medical Specialties (DiMI), University of Genoa, Genova, Italy ; Genetics of Rare Cancers, IRCCS Azienda Ospedaliera Universitaria San Martino, IST Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy.
authors: Paola
authors: P
authors: Ghiorzo
authors: Department of Medical Oncology, IRCCS Azienda Ospedaliera Universitaria San Martino, IST Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy.
authors: Laura
authors: L
authors: Orgiano
authors: Department of Internal Medicine and Medical Specialties (DiMI), University of Genoa, Genova, Italy ; Genetics of Rare Cancers, IRCCS Azienda Ospedaliera Universitaria San Martino, IST Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy.
authors: Lorenza
authors: L
authors: Pastorino
authors: Department of Medical Oncology, IRCCS Azienda Ospedaliera Universitaria San Martino, IST Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy.
authors: Virginia
authors: V
authors: Picasso
authors: Department of Medical Oncology, IRCCS Azienda Ospedaliera Universitaria San Martino, IST Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy.
authors: Elena
authors: E
authors: Tornari
authors: Department of Medical Oncology, IRCCS Azienda Ospedaliera Universitaria San Martino, IST Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy.
authors: Vincenzo
authors: V
authors: Ottaviano
authors: Department of Medical Oncology, IRCCS Azienda Ospedaliera Universitaria San Martino, IST Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy.
authors: Paola
authors: P
authors: Queirolo
keywords: BRAF; BRAF inhibitor; dabrafenib; melanoma; resistance; vemurafenib
references: N Engl J Med. 2015 Jan 1;372(1):30-9
references: 25399551
references: Nature. 2011 Nov 23;480(7377):387-90
references: 22113612
references: Am J Clin Pathol. 2011 Oct;136(4):527-39
references: 21917674
references: Cancer Lett. 2012 Jan 28;314(2):244-55
references: 22056813
references: Eur J Cancer. 2014 Feb;50(3):611-21
references: 24295639
references: Cancer Res. 2010 Jul 1;70(13):5213-9
references: 20551059
references: Cancer. 2014 Oct 15;120(20):3142-53
references: 24985732
references: PLoS One. 2013 Aug 20;8(8):e70826
references: 23976959
references: N Engl J Med. 2012 Jul 12;367 (2):107-14
references: 22663011
references: Nature. 2010 Dec 16;468(7326):968-72
references: 21107320
references: Mol Cell Probes. 2004 Oct;18(5):349-52
references: 15294323
references: Cancer Discov. 2013 Mar;3(3):350-62
references: 23288408
references: Lancet Oncol. 2012 Nov;13(11):1087-95
references: 23051966
references: Cancer Res. 2008 Jun 15;68(12):4853-61
references: 18559533
references: N Engl J Med. 2012 Jan 19;366(3):207-15
references: 22256804
references: Clin Cancer Res. 2013 Mar 1;19(5):1225-31
references: 23307859
references: Clin Cancer Res. 2012 Jun 15;18(12):3242-9
references: 22535154
references: Nature. 2002 Jun 27;417(6892):949-54
references: 12068308
references: Cancer Res. 2014 Apr 15;74(8):2340-50
references: 24576830
references: Cell Rep. 2014 May 8;7(3):645-53
references: 24746818
references: Br J Cancer. 2013 Mar 5;108(4):924-31
references: 23403819
references: Mol Cancer Ther. 2012 Apr;11(4):909-20
references: 22389471
references: Cancer. 2014 Jun 1;120(11):1695-701
references: 24577748
references: Cancer Immunol Immunother. 2014 May;63(5):449-58
references: 24609989
references: Nat Med. 2013 Nov;19(11):1401-9
references: 24202393
references: Nature. 2012 Jul 26;487(7408):505-9
references: 22763448
references: Clin Cancer Res. 2010 Dec 15;16(24):6040-8
references: 21169256
references: N Engl J Med. 2011 Dec 22;365(25):2439-41
references: 22188003
references: Semin Oncol. 2011 Apr;38(2):236-42
references: 21421113
references: Clin Cancer Res. 2012 Apr 15;18(8):2326-35
references: 22355009
references: J Clin Endocrinol Metab. 2004 Jun;89(6):2867-72
references: 15181070
references: Am J Surg Pathol. 2013 Jan;37(1):61-5
references: 23026937
references: Clin Cancer Res. 2013 Oct 15;19(20):5749-57
references: 23948972
references: Cancer Discov. 2012 May;2(5):414-24
references: 22588879
references: Trends Biochem Sci. 2011 Jun;36(6):320-8
references: 21531565
references: Clin Cancer Res. 2014 Mar 1;20(5):1074-80
references: 24352648
references: J Mol Diagn. 2011 Sep;13(5):467-73
references: 21708284
references: Nat Commun. 2012 Mar 06;3:724
references: 22395615
references: Nature. 2010 Mar 18;464(7287):427-30
references: 20179705
references: Cancer Res. 2013 Oct 15;73(20):6106-10
references: 24097822
references: Eur J Cancer. 2013 May;49(7):1654-61
references: 23481513
references: Lancet Oncol. 2012 May;13(5):459-65
references: 22456429
references: Nature. 2013 Feb 14;494(7436):251-5
references: 23302800
references: Arch Pathol Lab Med. 2012 Nov;136(11):1385-91
references: 22332713
references: Int J Exp Pathol. 2010 Dec;91(6):500-5
references: 21199003
references: Nature. 2012 Jul 26;487(7408):500-4
references: 22763439
references: N Engl J Med. 2010 Aug 19;363(8):711-23
references: 20525992
references: Oncogene. 2012 Jan 26;31(4):446-57
references: 21725359
references: Cancer Immunol Res. 2014 Jan;2(1):70-9
references: 24416731
references: J Mol Diagn. 2012 May-Jun;14 (3):247-55
references: 22425762
references: J Clin Oncol. 2011 Aug 1;29(22):3085-96
references: 21383288
references: Diagn Mol Pathol. 2012 Mar;21(1):1-8
references: 22306669
references: Am J Clin Pathol. 2013 Jun;139(6):759-64
references: 23690118
references: N Engl J Med. 2013 Jul 11;369(2):134-44
references: 23724846
references: J Clin Oncol. 2013 May 10;31(14 ):1767-74
references: 23569304
references: N Engl J Med. 2015 Jan 22;372(4):320-30
references: 25399552
references: Cancer Cell. 2011 Jan 18;19(1):11-5
references: 21251612
references: J Mol Diagn. 2007 Sep;9(4):464-71
references: 17690212
references: N Engl J Med. 2011 Jun 30;364(26):2517-26
references: 21639810
references: Clin Cancer Res. 2012 Mar 1;18(5):1386-94
references: 22156613
references: J Clin Oncol. 2013 Feb 1;31(4):482-9
references: 23248257
references: Cancer. 2014 Jun 1;120(11):1617-9
references: 24577788
references: Clin Cancer Res. 2013 Jan 15;19(2):393-403
references: 23204132
references: Cancer Discov. 2013 Mar;3(3):260-3
references: 23475878
references: J Transl Med. 2014 May 07;12 :116
references: 24885479
references: Crit Rev Oncol Hematol. 2014 Jul;91(1):74-92
references: 24530125
references: J Clin Oncol. 2012 May 10;30(14 ):1628-34
references: 22454415
references: Nat Genet. 2007 Mar;39(3):347-51
references: 17293865
references: BMC Cancer. 2014 Jan 10;14 :13
references: 24410877
references: Cancer Immunol Res. 2014 Jul;2(7):643-54
references: 24903021
references: J Clin Oncol. 2014 Apr 1;32(10):1020-30
references: 24590637
references: Cancer Discov. 2014 Jan;4(1):69-79
references: 24265152
references: Lancet Oncol. 2014 Mar;15(3):323-32
references: 24508103
references: J Mol Diagn. 2009 Mar;11(2):140-7
references: 19213871
references: Cancer Chemother Pharmacol. 2013 Jun;71(6):1395-409
references: 23443307
references: Cancer Invest. 2013 Jun;31(5):336-45
references: 23641913
references: N Engl J Med. 2013 Apr 4;368(14 ):1365-6
references: 23550685
references: Cancer Discov. 2013 Feb;3(2):158-67
references: 23242808
references: Clin Cancer Res. 2014 Apr 1;20(7):1965-77
references: 24463458
references: Ann Surg Oncol. 2013 Mar;20(3):759-66
references: 23179992
references: Lancet. 2012 Jul 28;380(9839):358-65
references: 22735384
references: Nature. 2014 Apr 3;508(7494):118-22
references: 24670642
references: Cancer Discov. 2014 Jan;4(1):80-93
references: 24265155
references: Cancer Invest. 2014 May;32(4):144-9
references: 24484235
references: Cancer Res. 2011 Aug 1;71(15):5067-74
references: 21803746
references: Cancer Discov. 2014 Jan;4(1):94-109
references: 24265153
references: Cancer Res. 2011 Apr 1;71(7):2750-60
references: 21317224
references: J Neurooncol. 2014 May;118(1):109-16
references: 24532241
references: Cancer Discov. 2013 Mar;3(3):338-49
references: 23171796
references: Proc Natl Acad Sci U S A. 2009 Dec 1;106(48):20411-6
references: 19915144
references: CA Cancer J Clin. 2014 Jan-Feb;64(1):9-29
references: 24399786
references: N Engl J Med. 2014 Nov 13;371(20):1867-76
references: 25265494
references: Mol Cancer Ther. 2008 Sep;7(9):2876-83
references: 18790768
references: J Mol Diagn. 2013 Jan;15(1):94-100
references: 23159108
references: J Clin Oncol. 2013 Sep 10;31(26):3205-11
references: 23918947
references: Eur J Cancer. 2013 Mar;49(5):1073-9
references: 23237741
references: N Engl J Med. 2012 Nov;367 (18):1694-703
references: 23020132
references: Mol Cancer Ther. 2013 Jul;12(7):1332-42
references: 23645591
references: J Natl Cancer Inst. 2014 Feb;106(2):djt443
references: 24511111
references: Ann Oncol. 2013 Aug;24(8):2174-80
references: 23666915
references: Nature. 2010 Dec 16;468(7326):973-7
references: 21107323
references: Clin Cancer Res. 2013 Sep 1;19(17):4868-78
references: 23833299
references: Melanoma Res. 2014 Feb;24(1):61-7
references: 24121190